Yuya Takakubo

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Expression of Toll-like Receptors and Their Signaling Pathways in Rheumatoid Synovitis

Yasunobu Tamaki, Yuya Takakubo, Tomoyuki Hirayama et al. · The Journal of Rheumatology · 2011 · 75 citations · Full text

Toll‐like receptors in the interface membrane around loosening total hip replacement implants

Michiaki Takagi, Yasunobu Tamaki, Hiroshi Hasegawa et al. · Journal of Biomedical Materials Research Part A · 2007 · 73 citations

Toll‐like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide‐coated titanium particles

Tomoyuki Hirayama, Yasunobu Tamaki, Yuya Takakubo et al. · Journal of Orthopaedic Research® · 2011 · 69 citations